

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

Application Number	10/583,927
Filing Date	December 23, 2004
First Named Inventor	Sek Chung Fung
Art Unit	1643
Examiner Name	Stephen L. Rawlings
Attorney Docket No.	12279-187-999

U.S. PATENT DOCUMENTS

*Examiner Initials	Cite No.	Document Number -- Kind Code	Publication Date mm/dd/yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A21	US 2010-0266494 A1	10/21/2010	Fung et al.	
	A22	US 2003-235555 A1	12/25/2003	Shealey et al.	
	A23	5652123	7/27/1997	Caput et al.	
	A24	5717072	2/10/1998	Mosley et al.	
	A25	5965709	10/12/1999	Presta et al.	
	A26	5994514	11/20/1999	Jardieu et al.	
	A27	6037453	3/14/2000	Jardieu et al.	
	A28	6,143,871	11/07/2000	Bonnefoy et al.	
	A29	6299875	10/09/2001	Caplan et al.	
	A30	6329509	12/11/2001	Jardieu et al.	
	A31	6576232 B1	6/10/2003	Debinski et al.	
	A32	6664227	12/16/2003	Wynn et al.	
	A33	6743604	6/01/2004	Bonnefoy et al.	
	A34	7,615,213 B2	11/10/2009	Kasaian et al.	
	A35	7,674,459 B2	03/09/2010	Fung et al.	

FOREIGN PATENT DOCUMENTS

*Examiner Initials	Cite No.	Foreign Patent Document Country Code, Number, Kind Code (if known)	Publication Date mm/dd/yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
	B24	EP 0876482 (B1)	03/19/2003	Sanofi SA [FR] (in French with English Abstract)		
	B25	EP 1141286 (B1)	10/18/2006	Genetics Inst [US] and Univ Johns Hopkins [US]		
	B26	JP 2007-161724 (corresponding to WO 2005/062967)	06/28/2007	Tanox Inc. (in Japanese with English Abstract)		
	B27	JP 2008-500024 (corresponding to WO 2005/062967)	01/10/2008	Tanox Inc. (in Japanese with English Abstract)		
	B28	WO 97/20926 (A1)	06/12/1997	Sanofi SA [FR] et al. (in French with English Abstract)		
	B29	WO 00/23410 A2	4/27/2000	Bayer AG		

NYI-4245742

EXAMINER SIGNATURE

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SR/

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

Application Number	10/583,927
Filing Date	December 23, 2004
First Named Inventor	Sek Chung Fung
Art Unit	1643
Examiner Name	Stephen L. Rawlings
Attorney Docket No.	12279-187-999

FOREIGN PATENT DOCUMENTS

*Examiner Initials	Cite No.	Foreign Patent Document Country Code, Number, Kind Code (if known)	Publication Date mm/dd/yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
	B30	WO 00/444074 A2	8/03/2000	Amgen Canada		
	B31	WO 01/34645 A2	5/17/2001	The Govt of the USA		
	B32	WO 01/92514 A1	6/12/2001	Shanghai Biowindow Gene Development Inc.		
	B33	WO 03/035847 A2	5/01/2003	Centocor, Inc.		
	B34	WO 03/086451 A1	10/23/2003	Centocor, Inc.		
	B35	WO 2003/040164 A2	5/15/2003	Cytos Biotechnology AG [CH]		
	B36	WO 2004/001655 A1	12/31/2003	Office of Technology Transfer, Dept. of Health and Human Services representing Government of United States of America		
	B37	WO 2004/019974 A2	3/11/2004	Glaxo Group Ltd [GB]		
	B38	WO 2004/019979 A2	3/11/2004	Glaxo Group Ltd [GB]		
	B39	WO 2005/121177 A2	12/22/2005	Wyeth		
	B40	WO 2005/123126 A2	12/29/2005	Wyeth		
	B41	WO 2007/036745 (A2, A3)	04/05/2007	Cambridge Antibody Tech [GB] et al.		
	B42	WO 2007/045477 (A2, A3)	04/26/2007	Novartis AG [CH] ; Novartis Pharma GMBH [AT]		

NON PATENT LITERATURE DOCUMENTS

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C72	"Monoclonal Anti-Human IL-13 Antibody." R&D Systems, Inc. Catalog [on-line], October 2002 [retrieved on October 14, 2002]. Retrieved from the Internet: < URL: http://www.rndsystems.com/aspc/search.asp?category=3&factors=IL%2D13 >.	
	C73	AILERS et al., 2002, "A push-pull approach to maximize vaccine efficacy: abrogating suppression with an IL-13 inhibitor while augmenting help with granulocyte/macrophage colony-stimulating factor and CD40L." Proc Natl Acad Sci U S A: 99(20):13020-5	
	C74	AKBARI et al., 2003, "Essential role of NKT cells producing IL-4 and IL-13 in the development of allergen-induced airway hyperreactivity." Nat Med. 9(5):582-8	
	C75	ALBERTS et al., 1994, "An antibody molecule is composed of two identical light chains and two identical heavy chains." Molecular Biology of the Cell, Third Edition, Garland Publishing, Inc., New York, pp. 1208-1209	
	C76	AMRAD CORPORATION, Ltd. "IL-13 Receptor Antibody Project." August 17, 2005	
	C77	ARIMA et al., 2002, "Upregulation of IL-13 concentration in vivo by the IL13 variant associated with bronchial asthma." J Allergy Clin Immunol. 109(6):980-7	
	C78	ARIMA et al., 2005, "Characterization of the interaction between interleukin-13 and interleukin-13 receptors." J Biol. Chem. Vol. 280(26):24915-24922	

NYI-4245742

**EXAMINER
SIGNATURE****DATE CONSIDERED**

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SR/

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

Application Number	10/583,927
Filing Date	December 23, 2004
First Named Inventor	Sek Chung Fung
Art Unit	1643
Examiner Name	Stephen L. Rawlings
Attorney Docket No.	12279-187-999

NON PATENT LITERATURE DOCUMENTS

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
	C79	ASTHMA AND ALLERGY FOUNDATION OF AMERICA and The National Pharmaceutical Council, "A Closer Look at Asthma" A joint publication of AAFA and NPC, pp. 1-6	
	C80	BLEASE et al., 2001, "Therapeutic effect of IL-13 immunoneutralization during chronic experimental fungal asthma," J. Immunol., Vol. 165:5219-5224	
	C81	BREWER et al., 2004, "Inhibition of key cytokines by tetrathiomolybdate in the bleomycin model of pulmonary fibrosis," J. Inorg. Biochem. 98(12):2160-7	
	C82	BROWN et al., 1989, "A family of small inducible proteins secreted by leukocytes are members of a new superfamily that includes leukocyte and fibroblast-derived inflammatory agents, growth factors, and indicators of various activation processes." J. Immunol. 142(2):679-87	
	C83	CARRINGTON, B., "BIAcore analysis of hIL-13Ra2 binding/blocking to hIL-13 pre-bound to antibody JES10-5A2 or antibody 213," June 7, 2007, UCB Celltech, pp. 1-3	
	C84	COHN et al. 1998, "Cutting Edge: IL-4-independent induction of airway hyperresponsiveness by Th2, but not Th1, cells," J. Immunol. Vol.161:3813-3816	
	C85	COHN et al., 1997, "Induction of airway mucus production by T helper 2 (Th2) cells: a critical role for interleukin 4 in cell recruitment but not mucus production," J. Exp. Med. Vol.186(10):1737-1747	
	C86	DANIELS et al., 2004, "Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis." J. Clin. Invest. 114(9):1308-16	
	C87	DE SWART et al., 2002, "Immunization of macaques with formalin-inactivated respiratory syncytial virus (RSV) induces interleukin-13-associated hypersensitivity to subsequent RSV infection. J. Virol. 76(22):11561-9	
	C88	Dorland's Illustrated Medical Dictionary, 28 th ed., 1994, p. 151	
	C89	ENCYCLOPEDIA BRITANNICA'S GUIDE TO THE NOBEL PRIZES, 2007, "Immune system disorders," [on-line], June 27, 2007 [retrieved on June 27, 2007], pp. 1-4, Retrieved from the Internet:< URL: http://www.britannica.com/nobelprize/article-215507 >	
	C90	HASEGAWA et al., 2003, "Serum levels of tumor necrosis factor and interleukin-13 are elevated in patients with localized scleroderma." Dermatology. 207(2):141-7	
	C91	HELLER et al., 2002, "Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells." Immunity. 17(5):629-38	
	C92	HELLER et al., 2005, "Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution." Gastroenterology. 129(2):550-64	
	C93	HERSHEY GK., 2003, "IL-13 receptors and signaling pathways: an evolving web." J. Allergy Clin. Immunol. 111(4):677-90	
	C94	International Search Report mailed August 17, 2006 for PCT International Patent Application No. PCT/US2004/43301	
	C95	International Search Report mailed August 2, 2005 for PCT International Patent Application No. PCT/US2004/43341	
	C96	JAKUBZICK et al., 2003, "Therapeutic attenuation of pulmonary fibrosis via targeting of IL-4- and IL-13-responsive cells." J. Immunol. 171(5):2684-93	
	C97	JANEWAY et al., Chapter 11, 3 rd ed. of Immunobiology, 1997	
	C98	JANEWAY et al., Chapter 12, 3 rd ed. of Immunobiology, 1997	
	C99	JANEWAY et al., Section 9.18, 3 rd ed. of Immunobiology, 1997	
	C100	KAWAKAMI et al., 2002, "Intratumor administration of interleukin 13 receptor-targeted cytotoxin induces apoptotic cell death in human malignant glioma tumor xenografts." Mol. Cancer Ther. 1(12):999-1007	
	C101	KEANE et al., 1999, "IFN-gamma-inducible protein-10 attenuates bleomycin-induced pulmonary fibrosis via inhibition of angiogenesis." J. Immunol. 163(10):5686-92	

NYI-4245742

**EXAMINER
SIGNATURE**

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SR/

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

Application Number	10/583,927
Filing Date	December 23, 2004
First Named Inventor	Sek Chung Fung
Art Unit	1643
Examiner Name	Stephen L. Rawlings
Attorney Docket No.	12279-187-999

NON PATENT LITERATURE DOCUMENTS

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C102	KEANE et al., 1999, "Neutralization of the CXCL chemokine, macrophage inflammatory protein-2, attenuates bleomycin-induced pulmonary fibrosis." J Immunol. 162(9):5111-8	
	C103	KIM et al., 2002, "IL-13-induced Clara cell secretory protein expression in airway epithelium: role of EGFR signaling pathway." Am. J. Physiol. Lung Cell Mol. Physiol. 283:L67-L75	
	C104	KUPERMAN et al., 2002, "Direct effects of interleukin-13 on epithelial cells cause airway hyperreactivity and mucus overproduction in asthma." Nat. Med. 8(8):885-9 (copy of advanced online publication available)	
	C105	LAPORTE et al., 2008, "Molecular and structural basis of cytokine receptor pleiotropy in the interleukin-4/13 system." Cell. Vol. 132(2):259-272 (HHMI Author Manuscript)	
	C106	LAUDER & MCKENZIE, 2001, "Measurement of Interleukin-13," Current Protocols in Immunology, Unit 6.18, Supplement 46, 6.18.1-6.18.6, John Wiley & Sons, Inc., New York	
	C107	LEE et al., 2001, "Serum levels of interleukins (IL)-4, IL-5, IL-13, and interferon-gamma in acute asthma." J. Asthma. 38(8):665-71	
	C108	LIU et al., 2004, "Regulation of found in inflammatory zone 1 expression in bleomycin-induced lung fibrosis: role of IL-4/IL-13 and mediation via STAT-6." J. Immunol. 173(5):3425-31	
	C109	LUKACS et al., 2001, "Respiratory syncytial virus predisposes mice to augmented allergic airway responses via IL-13-mediated mechanisms." J. Immunol. 167(2):1060-5	
	C110	MADHANKUMAR et al., 2002, "Alanine-scanning mutagenesis of alpha-helix D segment of interleukin-13 reveals new functionally important residues of the cytokine." J Biol Chem. 277(45):43194-205	
	C111	MATSUSHITA et al., 2004, "Upregulation of interleukin-13 and its receptor in a murine model of bleomycin-induced scleroderma." Int. Arch. Allergy Immunol. 135(4):348-56	
	C112	MERCK MANUAL - ONLINE MEDICAL DICTIONARY, "Hyperimmunoglobulinemia E Syndrome" [online], July 7, 2007 [Retrieved on July 7, 2007]. Retrieved from the Internet: <URL: http://www.merck.com/mmhe/sec16/ch184k.html >, pp. 1-2.	
	C113	MILLOUX et al., 1997, "Cloning of the human IL-13R alpha chain and reconstitution with the IL4R alpha of a functional IL-4/IL-13 receptor complex." FEBS Lett. 401(2-3):163-6	
	C114	MUELLER et al., 2002, "Structure, binding, and antagonists in the IL-4/IL-13 receptor system." Biochimica et Biophysica Acta. Vol. 1592(3):237-250	
	C115	OKUMA et al., 2004, "C-C chemokine receptor 2 (CCR2) deficiency improves bleomycin-induced pulmonary fibrosis by attenuation of both macrophage infiltration and production of macrophage-derived matrix metalloproteinases." J. Pathol. 204(5):594-604	
	C116	OXFORD CONCISE MEDICAL DICTIONARY, "Atopy," Fourth Edition 1994, Oxford University Press, Great Britain, pp. 54-55	
	C117	PEEBLES et al., 2001, "Immune interaction between respiratory syncytial virus infection and allergen sensitization critically depends on timing of challenges." J Infect Dis. 184(11):1374-9	
	C118	REBECK et al., 1987, "Homology" In Proteins And Nucleic Acids: A Terminology Muddle And A Way Out Of It. Cell. 50(5):667	
	C119	ROBERGE et al., 1998, "Treatment of uveitis with recombinant human interleukin-13." Br J Ophthalmol. 82(10):1195-8	
	C120	RUDIKOFF et al., 1982, "Single amino acid substitution altering antigen-binding specificity." Proc. Nat'l Acad. Sci. U.S.A., Vol. 79(6): 1979-1983.	
	C121	SCHACKER et al., 2002, "Collagen deposition in HIV-1 infected lymphatic tissues and T cell homeostasis." J. Clin. Invest. 110(8):1133-9	
	C122	SINGER et al., 1998, "Gens and Genoms", Moscow, Mir. 1988, Vol. 1, p. 63 (In Russian with English translation)	T
	C123	TABER'S CYCLOPEDIA MEDICAL DICTIONARY, "Atopy," 18th Edition, F.A. Davis Company, Philadelphia, 1993, p. 170	

NY1-4245742

**EXAMINER
SIGNATURE**

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SR/

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

Application Number	10/583,927
Filing Date	December 23, 2004
First Named Inventor	Sek Chung Fung
Art Unit	1643
Examiner Name	Stephen L. Rawlings
Attorney Docket No.	12279-187-999

NON PATENT LITERATURE DOCUMENTS

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
	C124	TEPLYAKOV et al., 2009, "Epitope mapping of anti-interleukin-13 neutralizing antibody CNT0607," J. Mol. Biol. Vol. 389(1):115-123	
	C125	TEPLYAKOV et al., 2010, "On the domain pairing in chimeric antibodies," Mol. Immunol. Vol. 47(14):2422-2426	
	C126	THOMPSON et al., 1999, "Mutants of interleukin 13 with altered reactivity toward interleukin 13 receptors," J. Biol. Chem., Vol. 274(42):29944-29950	
	C127	TSARBOPOULOS et al., 2000, "Mass spectrometric mapping of disulfide bonds in recombinant human interleukin-13," J. Mass. Spectrom., Vol. 35(3):446-453	
	C128	VITA et al., 1995, "Characterization and comparison of the interleukin 13 receptor with the interleukin 4 receptor on several cell types," J. Biol. Chem. 270(8):3512-3517	
	C129	WARDEMANN et al., 2003, "Predominant autoantibody production by early human B cell precursors," Science Vol. 301(5638):1374-1377	
	C130	WIKIPEDIA entry for "Hypersensitivity" [on-line], [Retrieved on July 2, 2007], pp. 1-4, Retrieved from the Internet:< URL: http://en.wikipedia.org/wiki/Hypersensitivity >	
	C131	WILLS-KARP M., 2004, " Interleukin-13 in asthma pathogenesis," Curr. Allergy Asthma Rep. 4(2):123-31.	
	C132	ZUEGG et al., 2001, "Structural model of human IL-13 defines the spatial interactions with the IL-13Rα/IL-4Rα receptor," Immunol. Cell Biol. Vol. 79(4):332-339	

NYI-4245742

EXAMINER SIGNATURE	/Stephen Rawlings/	DATE CONSIDERED	02/24/2011
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SR/